Internal Medicine, Endocrinology, Diabetes, & Metabolism · Merrillville, IN
NPI
1194104059
Since 2015
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
3
Medicare group memberships
Hospitals
4
Hospital affiliations
200 E 89th Ave # B
Merrillville, IN, 46410
Phone (219) 644-3939
Groups this clinician bills Medicare through
Medicare paid, 2024
$48K
723 services
Medicare patients, 2024
225
Average age 69
Drug cost, 2024
$1.9M
3,585 prescriptions
Company payments, 2025
$25K
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Pooja P Kinkhabwala was code 99232 (hospital e&m - subsequent), 228 times for 67 patients. In total Pooja P Kinkhabwala billed 723 services in 14 codes, and Medicare paid $48K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-03-14.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 228 | 67 | $56.10 | $13K |
| 99214 Office E&M - Established | Facility | 216 | 106 | $71.27 | $15K |
| 99222 Hospital E&M - Initial | Facility | 122 | 105 | $90.84 | $11K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 35 | 31 | $12.25 | $429 |
| 95251 Test - Miscellaneous | Facility | 31 | 21 | $25.81 | $800 |
| 99204 Office E&M - New | Facility | 24 | 24 | $92.05 | $2,209 |
| 99205 Office E&M - New | Facility | 18 | 18 | $133.06 | $2,395 |
| 99215 Office E&M - Established | Facility | 17 | 16 | $106.50 | $1,810 |
By year: 2022 $48K for 759 services; 2023 $40K for 612 services; 2024 $48K for 723 services.
Medicare prescription drug claims, 2024
In 2024, the drug Pooja P Kinkhabwala prescribed most often to Medicare patients was Atorvastatin Calcium, with 354 prescriptions and refills. In total Pooja P Kinkhabwala wrote 3,585 Medicare prescriptions that cost $1.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Atorvastatin Calcium Generic | 354 | 983 | 135 | $2,148 |
| Levothyroxine Sodium Generic | 283 | 774 | 89 | $2,748 |
| Jardiance Empagliflozin | 192 | 453 | 69 | $263K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 142 | 268 | 76 | $13K |
| Metformin Hcl Generic | 139 | 376 | 53 | $867 |
| Rosuvastatin Calcium Generic | 135 | 392 | 54 | $1,359 |
| Ozempic Semaglutide | 133 | 189 | 40 | $169K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 99 | 219 | 55 | $10K |
| Mounjaro Tirzepatide | 84 | 98 | 21 | $102K |
| Isturisa Osilodrostat Phosphate | 80 | 80 | 14 | $599K |
| Cinacalcet Hcl Generic | 75 | 150 | 24 | $41K |
| Hydrocortisone Generic | 68 | 135 | 18 | $3,153 |
| Trulicity Dulaglutide | 67 | 76 | 18 | $74K |
| Liothyronine Sodium Generic | 63 | 157 | 23 | $2,257 |
| Synthroid Levothyroxine Sodium | 57 | 115 | 13 | $4,290 |
Brand drugs: 1,443 claims; generic drugs: 1,834 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Pooja P Kinkhabwala $25K ($25K in general payments such as food, travel and fees) from 12 companies. The largest payer was Kyowa Kirin, Inc. with $13K.
| Company | Payments | Amount |
|---|---|---|
| Kyowa Kirin, Inc. 4151.T | 29 | $13K |
| Recordati_rare_diseases_inc. | 6 | $5,852 |
| Abbott Laboratories ABT | 16 | $4,182 |
| Medtronic, Inc. MDT | 6 | $570 |
| Amgen Inc. AMGN | 13 | $566 |
| Alexion Pharmaceuticals, Inc. AZN | 2 | $270 |
| Insulet Corporation PODD | 3 | $200 |
| Novo Nordisk Inc NVO | 2 | $51.28 |
| Sequel Med Tech, LLC | 2 | $42.04 |
| Ascensia Diabetes Care Us Inc. | 2 | $41.04 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.